Skip to main content
Equibles
GUTS logo

GUTS · Fractyl Health, Inc.

Track GUTS — free

Use GUTS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about GUTS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.68 +0.02 (+2.72%) At close · Aug 14
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“However, these existing cash resources are not expected to be sufficient to fund the Company's current operating plan for at least twelve months from the issuance date of this Quarterly Report on Form 10-Q. As a result, substantial doubt exists about the Company's ability to continue as a going concern for at least one year after the date that these financial statements are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$108.24M
Shares
159.18M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.68 Open$0.68 Day$0.66–0.70 52W close$0.39–2.37 Avg vol 30d1.7M Short int3.1M · 2.0% float · 1.8d Short vol57% Last earningsAug 10, 2026 DataFeb 2024–Aug 2026 Filing10-Q · Aug 10

Up next

Next earnings call
Oct 15, 2026 Est · unconfirmed · in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Strong Sell Momentum Neutral Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Strong Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −32%
      below
      Price vs 50-day avg −10%
      below
      RSI (14) 43
      neutral
      MACD trend Negative
      52-week position 15%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Neutral
      1-month return −16%
      trailing
      6-month return +43%
      trailing
      YTD return −69%
      this year
      Relative strength +30%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 200d above 50d
      Institutional flow Distributing
      -11% holders QoQ · +12 funds added
      Insider flow Accumulating
      Net +$127.4K over 90 days · 0% sells
      Short interest Rising
      1.96% of float · ▲ +23.8% MoM · 1.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      75 holders — mid 2-yr range
      Squeeze score 50
      elevated · 0–100
      Fundamentals
      Weak
      Revenue growth −100%
      Y/Y
      EPS growth −15%
      Y/Y
      Free cash flow $-90.9M
      Balance sheet $81.5M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 114%
      annualized · 1-yr
      Max drawdown −83%
      past year
      ATR 7.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 3 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −32% Bearish
      Price vs 50-day avg
      −10% Bearish
      RSI (14)
      43 Neutral
      MACD trend
      Negative Bearish
      52-week position
      15% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 200d above 50d
      Institutional flow Distributing
      -11% holders QoQ · +12 funds added
      Insider flow Accumulating
      Net +$127.4K over 90 days · 0% sells
      Short interest Rising
      1.96% of float · ▲ +23.8% MoM · 1.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      75 holders — mid 2-yr range
      Price context
      position in its 52-week range
      Range low $0 Now $1 · 15% Range high $2
      vs 200-day avg -32% vs 50-day avg -10%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted EBITDA non-GAAP $16.3M the quarter ended June 30, 2026 —
      Cash and cash equivalents $85.6M As of January 2, 2026 —
      Granted U.S. patents 35 As of January 5, 2026 —
      Pending U.S. patent applications 45 As of January 5, 2026 —
      Shares of common stock outstanding 153,372,044 As of December 31, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      GUTS
      Fractyl Health, Inc.
      this stock
      		$108.24M -69.1% -100.0% — 2.0%
      ONC
      BeOne Medicines Ltd.
      		 $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.94B +1.2% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      75
      % held
      41.4%
      Net QoQ
      -7.5M sh
      Top holder
      Nantahala Capital Managem…
      Held Float
      View
      Held by Funds
      Fund positions
      16
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      3.1M
      Days to cover
      1.8d
      Change
      +601.4K sh
      View
      Short Volume
      Short vol %
      57%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      500
      Value
      $395
      As of
      Jul 1, 2026
      View
      Off-Exchange
      Off-exchange %
      66.2%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Cluster buy
      Net (90d)
      +$127.4K
      Buyers / Sellers
      5 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Net income (FY)
      $-141.0M
      EPS diluted
      $-1.86
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Aug 12, 2026
      This year
      19
      View
      Proposed Sales
      Value
      $226.1K
      Shares
      111.9K
      Filed
      Jan 30, 2025
      View
      Exempt Offerings
      Offering
      $20.1M
      Filed
      Jan 25, 2022
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 12, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      GUTS -2.9% -16.1% +43.5% -0.7% -69.1%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -3.3% -20.5% +29.7% -4.7% -82.9%
      Key facts CIK 1572616 CUSIP 35168W103 13F (30d) 73 filings 73 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)